News and Press Releases

Freudenberg Medical Expands Coatings Business with New Production Facility

Investment of more than $50m to meet growing global demand for drug and hydrophilic coatings for medical devices and components Manufacturing footprint tripled with new 130,000sqft facility in the Aachen...

Category: Manufacturing and Packing, Other, Pharmaceutical
Posted: June 11, 2024

Freudenberg Medical Europe GmbH Liebigstraße 2-8 67661 Kaiserslautern Germany

Discovery Park partners with Canterbury Christ Church University to open CoLab, a new coworking labspace for early stage life sciences businesses

New space recognises the need for more cost-effective bench space and flexible agreements for startups and spinouts  10 June 2024 -- Kent, UK -- Discovery Park, Kent’s thriving life sciences...

Category: Biotechnology, Drug Discovery, Pharmaceutical
Posted: June 10, 2024

Discovery Park, Innovation House, Sandwich, Kent, CT13 9FF

Oxford Drug Design and CRUK Scotland Institute awarded MRC grant funding to advance novel cancer therapeutics discovery

Collaboration to use genetically engineered mouse models to validate a new approach to cancer therapy 4 June 2024 - United Kingdom - The CRUK (Cancer Research UK) Scotland Institute and Oxford...

Category: Drug Discovery
Posted: June 10, 2024

Oxford Drug Design Lt,d Oxford Centre for Innovation, New Road, Oxford, OX1 1BY, UK

GSK’s Omjjara▼ (momelotinib) is accepted for use within NHS Scotland, in line with its licence, for eligible adult myelofibrosis patients with moderate to severe anaemia

Clinicians in Scotland will now have the option to use momelotinib for the treatment of disease-related splenomegaly or symptoms in adult myelofibrosis patients with moderate to severe anaemia Momelotinib is...

Category: Other, Pharmaceutical
Posted: June 10, 2024

980 Great West Rd, London TW8 9GS

Leveraging its strategic location, advanced infrastructure and capabilities, Abu Dhabi is Underway to Become a Global Pharmaceutical and Life Science Distribution Hub

An MoU was signed by DoH, ADIO, Etihad Airways and AD Ports Group during the prestigious BIO International Convention in California, US, which took place 3-6 June The partnership aims...

Category: Other, Pharmaceutical
Posted: June 7, 2024

Building 35 Kanadel Street, Al Rawda – Abu Dhabi - Postal code 20224

Telstar to join Syntegon

Telstar will join the Germany-based company following the transaction that has been announced by Azbil Corporation and Syntegon 7 June 2024 -- Barcelona, Spain -- Regarding the integration of Telstar...

Category: Logistics, Manufacturing and Packing, Pharmaceutical
Posted: June 7, 2024

Av. Font i Sagué, 55, Tecnològic Orbital 40, 08227 Terrassa, Barcelona, Spain

New US headquarters opened by mass photometry pioneers Refeyn

Refeyn staff join mass photometry inventor Prof Philipp Kukura in cutting ribbon to Refeyn’s new US customer interaction centre in Massachusetts’ Waltham Biotech Hub 6 June 2024 -- Oxford, UK...

Category: BioManufacturing, Drug Discovery, Pharmaceutical
Posted: June 6, 2024

Unit 9, Trade City, Sandy Ln W, Oxford OX4 6FF, United Kingdom

Canopy Growth Establishes $250m At-The-Market Programme To Further Enhance the company’s Financial Position And Facilitate Growth

6 June 2024 -- Ontario, Canada -- Canopy Growth Corporation, a world-leading cannabis company dedicated to unleashing the power of cannabis to improve lives, announced today that the company has...

Category: Other, Pharmaceutical
Posted: June 6, 2024

1 Hershey Drive Smiths Falls, Ontario K7A 0A8

Vetter announces plans to expand its capacity in the US and Germany

Leading globally operating CDMO outlines location and design of new manufacturing sites to meet increasing customer demands Vetter Advisory Board decides on strategic path forward for further independent and sustainable...

Category: Manufacturing and Packing, Other, Pharmaceutical
Posted: June 6, 2024

Schützenstrasse 87, 88212 Ravensburg

Nuclera Awarded £1.14m Innovate UK Funding for Development of eProtein Discovery

£790,000 FASST grant, in collaboration with DeepMirror, and £350,000 Engineering Biology grant awarded for platform development 6 June 2024 -- Cambridge, UK -- Nuclera, the biotechnology company accelerating protein expression...

Category: BioManufacturing, Biotechnology, Drug Discovery, Pharmaceutical
Posted: June 6, 2024

One Vision Park, Station Road, Impington, Cambridge, CB24 9NP

Clinigen acquires boutique market access consultancy Ascenian to accelerate access to lifesaving treatments

6 June 2024 -- London, UK -- Clinigen, the global pharmaceutical services company, today announces the acquisition of Ascenian, a boutique global market access consultancy. Together the combined companies will...

Category: Other, Pharmaceutical
Posted: June 6, 2024

25 Bedford Square Bloomsbury London WC1B 3HH

Kite Receives European Medicines Agency Approval of Safety Monitoring Variation for CAR T-Cell Therapy Portfolio

In-hospital patient monitoring for adverse events reduced from ten to seven days following CAR T-cell therapy infusion 6 June 2024 -- Stockley Park, UK -- Kite, a Gilead Company, today...

Category: Biotechnology, Other, Pharmaceutical
Posted: June 6, 2024

2400 Broadway Santa Monica, CA 90404

MediMab Biotherapeutics opens bespoke laboratory facilities, created by Kadans Science Partner, at Abingdon Science Park, UK

New CL2 wet lab purpose-built facilities delivered by Kadans Science Partner will support MediMab Biotherapeutics to identify first-in-class immuno-oncology drugs that can actively target a range of advanced and solid...

Category: Biotechnology, Manufacturing and Packing, Pharmaceutical
Posted: June 6, 2024

Rijksweg 5 5076 PB Haaren The Netherlands

SYS6002 (CRB-701) A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate Continues to Demonstrate Encouraging Safety and Efficacy Observed in Patients with Nectin-4 Positive Tumours in a Clinical Update Presented at ASCO 2024

An additional 19 patients have been enrolled since January 2024 bringing the total to 37 of whom 25 were evaluable for efficacy SYS6002 (CRB-701) demonstrated 44% ORR and 78% DCR in...

Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: June 5, 2024

500 River Ridge Drive Norwood, MA 02062

VALANX Biotech Announces Promising Results in First In-Vivo Study of Novel Protein Conjugate Therapy

Study demonstrates pre-clinical efficacy of lead programme VLX101 in treating autoimmune disease 5 June 2024 - Klosterneuburg, Austria - VALANX Biotech, a biotech company developing novel technology for site-specific protein...

Category:
Posted: June 5, 2024

VALANX Biotech Gmbh, Plöcking 1, IST Park Building, 3400 Klosterneuburg, Austria